Yann Godfrin
Chief Executive Officer
Lyon, Auvergne-Rhone-Alpes, France
Professional Overview:
Yann Godfrin is a seasoned biotechnology and life sciences executive with over 18 years of experience leading innovative pharmaceutical and medical technology companies. As the Chief Executive Officer of Axoltis Pharma and the Founder and CEO of GODFRIN Life-Sciences, he brings a unique combination of entrepreneurial vision, scientific expertise, and strategic operational leadership to drive the development and commercialization of cutting-edge healthcare solutions.
Experience Summary:
Current Role
As the Chief Executive Officer of Axoltis Pharma since 2016, Yann oversees all aspects of the company's operations, including research and development, product pipeline management, and global commercialization efforts. Under his leadership, Axoltis has emerged as a leading player in the development of novel biopharmaceutical therapies, securing multiple strategic partnerships and advancing several promising drug candidates through the clinical pipeline.
Yann also serves as the Founder and CEO of GODFRIN Life-Sciences, a boutique consulting firm he established in 2016 to provide strategic advisory services to biotechnology and pharmaceutical companies on a range of critical business and operational matters.
Career Progression
Prior to his current roles, Yann co-founded ERYTECH Pharma in 2004, where he served as the company's CEO and Chief Scientific Officer, leading the development of its innovative red blood cell-based drug delivery platform. Under his guidance, ERYTECH Pharma successfully completed its initial public offering and advanced several clinical-stage programs.
Earlier in his career, Yann held the position of CEO at HEMOXymed Europe, where he was instrumental in establishing the company's European operations and advancing its pipeline of oxygen-carrying therapeutics.
Academic Background:
Yann holds a Ph.D. in Biochemistry and Molecular Biology from the University of Lyon, where he specialized in hematology and cell-based therapies. His academic achievements include several peer-reviewed publications and the co-invention of multiple patents related to his work in the field of red blood cell-based drug delivery.
Areas of Expertise:
- Biotechnology and pharmaceutical research and development
- Innovative drug delivery technologies
- Strategic business development and commercialization
- Regulatory affairs and clinical trial management
- Entrepreneurship and startup leadership
- Effective team building and organizational management
Professional Impact:
Under Yann's leadership, Axoltis Pharma has secured several strategic partnerships with global pharmaceutical companies, enabling the acceleration of its pipeline and the expansion of its reach into new markets. Additionally, his work at ERYTECH Pharma contributed to the advancement of novel cell-based therapies, with several of the company's drug candidates progressing through clinical trials.
Yann's expertise and industry contributions have been recognized through his appointment to the Board of Directors at Stromacare SAS, where he provides strategic guidance on the development of cutting-edge regenerative medicine solutions.
Conclusion:
With his exceptional track record of entrepreneurial success, scientific expertise, and strategic operational leadership, Yann Godfrin is poised to continue driving innovation and growth in the biotechnology and pharmaceutical sectors. As a visionary CEO and a respected industry thought leader, he is committed to improving patient outcomes and advancing the frontiers of healthcare through the development and commercialization of transformative life sciences solutions.
